Holen Sie sich die Stockscreener-App
6.85
4.74%
0.31
Handel nachbörslich:
6.85
Schlusskurs vom Vortag:
$6.54
Offen:
$6.61
24-Stunden-Volumen:
307.43K
Relative Volume:
0.44
Marktkapitalisierung:
$370.53M
Einnahmen:
$2.81M
Nettoeinkommen (Verlust:
$-97.34M
KGV:
-4.3354
EPS:
-1.58
Netto-Cashflow:
$-91.47M
1W Leistung:
-1.30%
1M Leistung:
-12.52%
6M Leistung:
+84.64%
1J Leistung:
-25.30%
1-Tages-Spanne:
$6.54
$6.925
1-Wochen-Bereich:
$6.275
$7.00
52-Wochen-Spanne:
$2.315
$10.13
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
Firmenname
Fulcrum Therapeutics Inc
Sektor
Branche
Telefon
617-651-8851
Adresse
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Vergleichen Sie FULC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
6.85 | 342.94M | 2.81M | -97.34M | -91.47M | -1.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-29 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-09-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | Herabstufung | Stifel | Buy → Hold |
| 2024-09-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-09-25 | Eingeleitet | Goldman | Neutral |
| 2023-08-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | Hochstufung | Stifel | Hold → Buy |
| 2023-05-04 | Herabstufung | Goldman | Buy → Neutral |
| 2023-03-10 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2023-02-28 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-15 | Eingeleitet | Goldman | Buy |
| 2022-03-08 | Eingeleitet | Oppenheimer | Outperform |
| 2022-03-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-08-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-02 | Eingeleitet | Stifel | Buy |
| 2020-10-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2019-10-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-08-12 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Fulcrum Therapeutics Inc Aktie (FULC) Neueste Nachrichten
Is Fulcrum Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Gains Report & Community Verified Trade Alerts - Newser
Technical signs of recovery in Fulcrum Therapeutics Inc.2025 Trading Volume Trends & Real-Time Market Trend Scan - Newser
Will Fulcrum Therapeutics Inc. rebound enough to break even [2025 Geopolitical Influence]Real-Time Volume Triggers - Newser
Using Ichimoku Cloud for Fulcrum Therapeutics Inc. technicals2025 Trade Ideas & Weekly Breakout Opportunity Watchlist - Newser
Forecasting Fulcrum Therapeutics Inc. price range with options dataBuy Opportunity Forecast for Fast Traders - Newser
What recovery options are there for Fulcrum Therapeutics Inc.Smart Entry Signals for Active Traders - Newser
Does Fulcrum Therapeutics Inc. qualify in momentum factor screeningBollinger Band Squeeze and Expansion Analysis - Newser
Is Fulcrum Therapeutics Inc. a Top Dividend Stock to Watch in 2025Free Short Term Buy Zone Stock Alerts - Newser
When is the best time to exit Fulcrum Therapeutics Inc.Free ROI Driven Equity Selection With Safety - Newser
Key External Factors That Drive Fulcrum Therapeutics Inc. Stock Price MovementsFree Safe Entry Stock Watch Suggestions - Newser
Comparing Fulcrum Therapeutics Inc. in custom built stock radarsSector Rotation Strategy for Smart Traders - Newser
How to interpret RSI for Fulcrum Therapeutics Inc. stockDaily Investment Ideas with Market Insight - Newser
Will Fulcrum Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsSecure Entry Point Finder with Analysis - Newser
How high can Fulcrum Therapeutics Inc. stock goOversold Stock Bounce Playbook Generator - Newser
Chart overlay techniques for tracking Fulcrum Therapeutics Inc.Sector-Wise Stock Strength Trend Analysis - Newser
Fulcrum defended at H.C. Wainwright after data for sickle cell disease drug - MSN
Why Fulcrum Therapeutics Inc. stock attracts strong analyst attentionWeekly Market Direction and Sector Summary - Newser
Fulcrum Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - The Globe and Mail
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Is Fulcrum Therapeutics Inc. stock ready for a breakoutLow Volatility Stock Analysis With Confidence - Newser
Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Lowered by Wall Street Zen - Defense World
Published on: 2025-08-09 00:54:39 - Newser
Fulcrum Therapeutics Awards $6.96 Stock Options Package: 4-Year Vesting Terms Revealed - Stock Titan
Real time pattern detection on Fulcrum Therapeutics Inc. stockPredicted Market Direction Based on Momentum - Newser
Quant Models Detect Momentum Reversal in Fulcrum Therapeutics Inc.Low Volatility Stable Growth Picks Rank High - beatles.ru
Fulcrum Therapeutics Reports Q2 2025 Financial Results - TipRanks
Technical Bounce Expected in Fulcrum Therapeutics Inc. Next WeekAI Based High Gain Watchlist Scanner Shared - beatles.ru
Strategy Insiders Buy In While Analysts Predict Big Upside - The Globe and Mail
Applying big data sentiment scoring on Fulcrum Therapeutics Inc.Buy Alert Based on RSI and Volume - Newser
Fulcrum Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with smart trades - Jammu Links News
What catalysts could drive Fulcrum Therapeutics Inc. stock higher in 2025Build wealth with long-term growth strategies - Jammu Links News
What are analysts’ price targets for Fulcrum Therapeutics Inc. in the next 12 monthsBuild a portfolio that stands the test of time - Jammu Links News
Why is Fulcrum Therapeutics Inc. stock attracting strong analyst attentionMassive stock growth - Jammu Links News
Is Fulcrum Therapeutics Inc. a good long term investmentUnlock powerful trading strategies for gains - Jammu Links News
What is the risk reward ratio of investing in Fulcrum Therapeutics Inc. stockBuild a winning investment strategy today - Jammu Links News
What analysts say about Fulcrum Therapeutics Inc. stockAchieve impressive returns with smart timing - Jammu Links News
What is Fulcrum Therapeutics Inc. company’s growth strategyUnlock powerful market insights for success - Jammu Links News
Fulcrum Therapeutics shares slide 17% after sickle cell trial results - MSN
Finanzdaten der Fulcrum Therapeutics Inc-Aktie (FULC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):